Maywan Hariono

Dr. Maywan Hariono

Faculty of Pharmacy, Sanata Dharma University
orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2015 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
SISyahrul Imran
Syahrul Imran
MTMuhammad Taha
Muhammad Taha
NINor Hadiani Ismail
Nor Hadiani Ismail
SKSyed Muhammad Kashif
Syed Muhammad Kashif
FRFazal Rahim
Fazal Rahim
HWHabibah A. Wahab
Habibah A. Wahab

1 September 2018 in Wound Medicine
Verified
Journal Article
Closed access
Maywan HarionoMaywan Hariono
Maywan Hariono
SYSri Hartati Yuliani
Sri Hartati Yuliani
EIEnade Perdana Istyastono
Enade Perdana Istyastono
FRFlorentinus D.O. Riswanto
Florentinus D.O. Riswanto
Christophorus AdhipanditoChristophorus Adhipandito
Christophorus Adhipandito

20 December 2016 in Scientific Reports
Verified
Journal Article
Open access
Maywan HarionoMaywan Hariono
Maywan Hariono
NANurshariza Abdullah
Nurshariza Abdullah
KDK.V. Damodaran
K.V. Damodaran
EKEzatul E. Kamarulzaman
Ezatul E. Kamarulzaman
NMNornisah Mohamed
Nornisah Mohamed
HWHabibah A. Wahab
Habibah A. Wahab
We report the computational and experimental efforts in the design and synthesis of novel neuraminidase (NA) inhibitors from ferulic acid and vanillin. Two proposed ferulic acid analogues, MY7 and MY8 were predicted to inhibit H1N1 NA using molecular docking. From these two analogues, we designed, synthesised and evaluated the biological activities of a series of ferulic acid and vanillin derivatives. The enzymatic H1N1 NA inhibition assay showed MY21 (a vanillin derivative) has the lowest IC50 of 50 μM. In contrast, the virus inhibition assay showed MY15, a ferulic acid derivative has the best activity with the EC50 of ~0.95 μM. Modelling studies further suggest that these predicted activities might be due to the interactions with conserved and essential residues of NA with ΔGbind values comparable to those of oseltamivir and zanamivir, the two commercial NA inhibitors.

17 November 2021 in Molecules
Verified
Journal Article
Open access
PDF file
Maywan HarionoMaywan Hariono
Maywan Hariono
JJJeffry Julianus
Jeffry Julianus
IDIpang Djunarko
Ipang Djunarko
IHIrwan Hidayat
Irwan Hidayat
LALintang Adelya
Lintang Adelya
PHPandu Hariyono
Pandu Hariyono
Carica papaya (papaya) leaf extract has been used for a long time in a traditional medicine to treat fever in some infectious diseases such as dengue, malaria, and chikungunya. The development of science and technology has subsequently made it possible to provide evidence that this plant is not only beneficial as an informal medication, but also that it has scientifically proven pharmacological and toxicological activities, which have led to its formal usage in professional health care systems. The development of formulations for use in nutraceuticals and cosmeceuticals has caused this product to be more valuable nowadays. The use of good manufacturing practice (GMP) standards, along with the ease of registering this product facilitated by policies of the national government, will absolutely increase the value of papaya leaf extract as a vital nutraceutical and cosmeceutical products in the near future. In this article, we review the potential of papaya leaf extract to be a high-value commodity in terms of its health effects as well as its industrial benefits.

24 January 2019 in PLOS ONE
Verified
Journal Article
Open access
PDF file
Maywan HarionoMaywan Hariono
Maywan Hariono
SCSy Bing Choi
Sy Bing Choi
RRRos Fatihah Roslim
Ros Fatihah Roslim
MNMohamed Sufian Nawi
Mohamed Sufian Nawi
MTMei Lan Tan
Mei Lan Tan
HWHabibah A. Wahab
Habibah A. Wahab
Dengue virus Type 2 (DENV-2) is predominant serotype causing major dengue epidemics. There are a number of studies carried out to find its effective antiviral, however to date, there is still no molecule either from peptide or small molecules released as a drug. The present study aims to identify small molecules inhibitor from National Cancer Institute database through virtual screening. One of the hits, D0713 (IC50 = 62 μM) bearing thioguanine scaffold was derivatised into 21 compounds and evaluated for DENV-2 NS2B/NS3 protease inhibitory activity. Compounds 18 and 21 demonstrated the most potent activity with IC50 of 0.38 μM and 16 μM, respectively. Molecular dynamics and MM/PBSA free energy of binding calculation were conducted to study the interaction mechanism of these compounds with the protease. The free energy of binding of 18 calculated by MM/PBSA is -16.10 kcal/mol compared to the known inhibitor, panduratin A (-11.27 kcal/mol), which corroborates well with the experimental observation. Results from molecular dynamics simulations also showed that both 18 and 21 bind in the active site and stabilised by the formation of hydrogen bonds with Asn174.

28 August 2021 in Molecules
Verified
Journal Article
Open access
PDF file
Muhammad Sulaiman ZubairMuhammad Sulaiman Zubair
Muhammad Sulaiman Zubair
SMSaipul Maulana
Saipul Maulana
AWAgustinus Widodo
Agustinus Widodo
RPRamadanil Pitopang
Ramadanil Pitopang
MAMuhammad Arba
Muhammad Arba
Maywan HarionoMaywan Hariono
Maywan Hariono
This study aims to identify and isolate the secondary metabolites of Zingiber officinale using GC-MS, preparative TLC, and LC-MS/MS methods, to evaluate the inhibitory potency on SARS-CoV-2 3 chymotrypsin-like protease enzyme, as well as to study the molecular interaction and stability by using docking and molecular dynamics simulations. GC-MS analysis suggested for the isolation of terpenoids compounds as major compounds on methanol extract of pseudostems and rhizomes. Isolation and LC-MS/MS analysis identified 5-hydro-7, 8, 2′-trimethoxyflavanone (9), (E)-hexadecyl-ferulate (1), isocyperol (2), N-isobutyl-(2E,4E)-octadecadienamide (3), and nootkatone (4) from the rhizome extract, as well as from the leaves extract with the absence of 9. Three known steroid compounds, i.e., spinasterone (7), spinasterol (8), and 24-methylcholesta-7-en-3β-on (6), were further identified from the pseudostem extract. Molecular docking showed that steroids compounds 7, 8, and 6 have lower predictive binding energies (MMGBSA) than other metabolites with binding energy of −87.91, −78.11, and −68.80 kcal/mole, respectively. Further characterization on the single isolated compound by NMR showed that 6 was identified and possessed 75% inhibitory activity on SARS-CoV-2 3CL protease enzyme that was slightly different with the positive control GC376 (77%). MD simulations showed the complex stability with compound 6 during 100 ns simulation time.